GettyImages 1150497210

Platform

Powering real progress with a discovery engine identifying new diagnostic protein biomarkers.

The Biomarker
Pipeline

Developing the future of cancer screening.

PROGRESS DISCOVERY VERIFICATION VALIDATION COMMERCIALIZED PATHTOMARKET CASESDIAGNOSEDANNUALLY 5 YRSURVIVALRATE Breast Cancer Screening Auria® LDT 290,560 29% Breast Cancer Screening Melody® 1.0 LDT 290,560 29% Prostate Cancer LDT 268,490 31% Pancreatic Cancer FDA* *Breakthrough Device *Breakthrough Device *Breakthrough Device 62,210 3% Colorectal Cancer LDT 151,030 15% Melanoma LDT (Lab Developed Test) NO FDA approval required.Namida could seek FDA device treatment for LDT’s in the future. *No current diagnostic test available FDA* 99,780 30% Ovarian Cancer FDA* 19,880 30% ASSESSMENT

Intellectual Property

Patents Granted

23

Methods of Detecting Cancer via Schirmer Strip
US PATENT 10,451,625

Methods of Detecting Cancer via Ocular Wash
US PATENT 10,613,090

Compositions & Methods for Diagnosing & Differentiating Systemic Juvenile Idiopathic Arthritis & Kawasaki Disease
US PATENT 11,448,648

Countries

18

Switzerland China Czech Rep. Germany Denmark France United Kingdom Hong Kong Ireland Italy Japan South Korea Netherlands Sweden Singapore Taiwan Canada China

Pending

4

To be filed

3

Systemic Juvenile Idiopathic Arthritis (SJIA) Kawasaki Disease

Diagnosis prospect for pediatric orphan disease.

Our
Capabilities

Clinical Trials, Research & Development, Testing & Commercialization

01

Clinical Trials

NCT# 04974567

Tear Based Sample Collection Breast Cancer Detection

Clinical Site

UTMB

Principal

Suzanne Klimberg MD, PHD

View Trial

NCT# 04928014

Validation of Melody, a Tear-based Screening Assay for Breast Cancer

Clinical Site

Parkhill Women’s Cinic

Principal

Paige Partridge, MD

View Trial

NCT# 05268224

Melody, a lab Developed Test for Breast Cancer for Women with Dense Breast Tissue

Clinical Site

MD Anderson

Principal

Teresa Bevers, MD

View Trial

02

Research & Development

Pioneering Proteomics

Our research laboratory uses proteomics to develop innovative cancer screening tools. Proteomics is the study of proteins, which are essential for the functioning of cells in the human body. By analyzing the proteins present in tears, we can identify unique biomarkers that indicate the presence of cancer. Our proteomics-based approach allows for earlier detection of cancer, which is crucial for effective treatment and improved patient outcomes.

NamidaLab2020 0239

03

CLIA Certified

The Clinical Laboratory Improvement Amendment (CLIA) passed in 1988 was established to provide quality standards, strengthen Federal oversight of clinical laboratories, and ensure the reliability and accuracy of patient test results. This program allows clinical labs to develop and validate their own testing protocols which can only be run in the lab where the protocol was validated.
Our CLIA certification gives our patients and healthcare providers confidence in the quality of our screening tests.
The qualification for a laboratory director of high complexity testing at 42 CFR 493.1443(b)(3)(i) is that the laboratory director must hold an earned doctoral degree in a chemical, physical, biological or clinical laboratory science from an accredited institution and be certified and continue to be certified by a board approved by HHS.

NamidaLab2020 7E7A0482

Let’s research.

We’re a revenue stage biotech company with big ideas, and the science to make them happen.

Be a part of the future of cancer screening.